Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

967805

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the UK leaving the EU on patient access to short-shelf life medicines.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	170342
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>The Government has made significant progress in negotiations with the European Union and remains confident the United Kingdom will leave with a good deal for both sides. This deal will include ensuring patients in the UK have access to appropriate, safe, and cost effective medicines, including short shelf-life medicines.</p><p> </p><p>However, as a responsible Government, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019. Therefore on 23 August 2018, the Department wrote to a number of pharmaceutical companies that supply medicines for National Health Service patients from, or via, the EU/European Economic Area (EEA), asking them to ensure that they have a minimum of six weeks additional supply in the UK, over and above their business as usual operational buffer stocks by 29 March 2019.</p><p> </p><p>For certain medicines with short shelf lives, which cannot be reasonably stockpiled, we are specifically asking that where these products are imported to the UK from the EU/EEA via road haulage and roll-on, roll-off sea, road and rail routes, suppliers ensure in advance plans to air freight these medicines to the UK. This will ensure that UK patients have the same access to these medicines as they currently do in unlikely event of the UK leaving the EU without a deal.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/09/2018 16:26:05 answering member 4067 label Biography information for Steve Brine
tabling member	4382 label Biography information for Daniel Zeichner

967869

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what guidance his Department received when determining the length of time medicines will need to be stockpiled in the event that the UK leaves the EU without a deal; if he will publish that guidance.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	170317
answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>As we set out in the Department’s letter to the pharmaceutical industry on 23 August, in the unlikely event we leave the European Union without a deal in March 2019, based on the current cross-Government planning scenario, we will ensure the United Kingdom has an additional six weeks supply of medicines in case imports from the EU through certain routes are affected. This is the current planning assumption but will of course be subject to revision in light of future developments.</p><p> </p><p>The Government has not asked the NHS to stockpile medicines. It has asked industry to make preparations for doing so.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 170318 question first answered 10/09/2018 16:13:06 answering member 4095 label Biography information for Steve Barclay
tabling member	4244 label Biography information for Jonathan Ashworth

967870

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse of the NHS stockpiling medicines for six weeks in the event that the UK leaves the EU without a deal; and whether that cost will be borne from existing Department of Health budgets.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	170318
answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>As we set out in the Department’s letter to the pharmaceutical industry on 23 August, in the unlikely event we leave the European Union without a deal in March 2019, based on the current cross-Government planning scenario, we will ensure the United Kingdom has an additional six weeks supply of medicines in case imports from the EU through certain routes are affected. This is the current planning assumption but will of course be subject to revision in light of future developments.</p><p> </p><p>The Government has not asked the NHS to stockpile medicines. It has asked industry to make preparations for doing so.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 170317 question first answered 10/09/2018 16:13:06 answering member 4095 label Biography information for Steve Barclay
tabling member	4244 label Biography information for Jonathan Ashworth

947297

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS in England of special medicinal products over the last 12 months.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	167951
answer	answer is ministerial correction date of answer 05/09/2018 answer text <p>In the most recent 12 month period for which data is available (June 2017 to May 2018) the cost of National Health Service special medicinal products dispensed in the community in England was £70.5 million down from £135.5 million in 2010.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/09/2018 10:25:43 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

946902

registered interest
date	23/07/2018
answering body	Department for Exiting the European Union
answering dept id	203
answering dept short name	Exiting the European Union
answering dept sort name	Exiting the European Union
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Exiting the European Union, what steps he has taken in negotiations on the UK leaving the EU to promote mutual access to medicines and drugs.
tabling member constituency	Belfast North
tabling member printed	Nigel Dodds
uin	167159
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>The UK is proposing a UK-EU free trade area, underpinned by a common rulebook. For industrial goods, including medicines, it would cover rules that set requirements for placing a product on the market. It would also feature bespoke provisions for human and animal medicines which reflect their unique status, and would be supplemented by continued UK participation in the European Medicines Agency. We look forward to continuing our negotiations with the EU on this issue.</p><p>In the unlikely event that it is not possible to reach a mutually satisfactory deal with the EU, the Department of Health and Social Care has already set outs its plans in technical notices to ensure that patients can continue to access medicines, including recognising batch-testing carried out in the EU.</p><p> </p> answering member constituency Worcester answering member printed Mr Robin Walker question first answered 14/09/2018 10:01:10 answering member 4091 label Biography information for Mr Robin Walker
tabling member	1388 label Biography information for Lord Dodds of Duncairn

947011

registered interest
date	23/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has undertaken an impact assessment on the potential beneficial effects of regulating the dispensing of special medicinal products in England.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	167294
answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>We have made no such assessment. The supply of special medicinal products is regulated in the United Kingdom by the Human Medicines Regulations 2012. In addition, in England, NHS dispensing by pharmacies is regulated by the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:00:47 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

942655

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Office for Life Sciences Competitiveness Indicators, published in May 2018, what assessment his Department has made of the fall in the uptake of NICE-approved medicines.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	164450
answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>The Competitiveness Indicators published by the Office for Life Sciences show that the relative uptake rates of National Institute for Health and Care Excellence (NICE)-approved medicines have remained broadly stable over the last five years, with an increase in the overall level of uptake in the first year after release being offset by a slight fall in the fourth and fifth years.</p><p> </p><p>There are a number of reasons why the levels of uptake may vary including changes in the reported basket of medicines, and country level differences in disease burden and clinical practice.</p><p> </p><p>In addition to the Competitiveness Indicators, NHS Digital publishes a report on the use of medicines by the National Health Service in England, known as the Innovation Scorecard. The latest publication from July 2018 shows that 71% of NICE-approved medicines had higher levels of uptake than in the previous 12 months.</p><p> </p><p>The Innovation scorecard is available at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard-to-december-2017" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard-to-december-2017</a></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/07/2018 10:44:23 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4382 label Biography information for Daniel Zeichner

942656

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Office for Life Sciences Competitiveness Indicators published in May 2018, what the reasons are for the reduction in the basic pharmaceuticals and pharmaceuticals products workforce between 2012 and 2016.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	164451
answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>The Competitiveness Indicators published by the Office for Life Sciences show that the number of people employed in the sector in the United Kingdom and other countries has fluctuated from year to year between 2007 and 2016. The figures published in this report are based on those collected by Eurostat which, in order to allow a consistent comparison between countries over time, do not capture the whole of the life sciences sector as it has evolved in recent years. The Government therefore commissions an additional ‘Strength and Opportunity’ report each year to collect more comprehensive figures on employment across the whole of the life sciences sector. The latest report published shows that employment rose from 113,400 in 2016 to 119,000 in 2017.</p><p> </p><p>The ‘Strength and Opportunity’ report is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/bioscience-and-health-technology-database-annual-report-2017" target="_blank">https://www.gov.uk/government/publications/bioscience-and-health-technology-database-annual-report-2017</a></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/07/2018 10:38:52 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4382 label Biography information for Daniel Zeichner

938471

registered interest
date	11/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information on the costs of goods he will require of manufacturers of special medicinal products under the Health Service Medical Supplies (Costs) Act 2017 and subsequent regulations; and if he will bring forward further regulatory proposals to control the costs of those products.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	163104
answer	answer is ministerial correction date of answer 16/07/2018 answer text <p>Under the Health Service Products (Provision and Disclosure of Information) Regulations 2018, manufacturers, importers and wholesalers of special medicinal products are required to provide the Department, every quarter, with purchase and/or sales information about products already listed with a price in the Drug Tariff and products that are being considered for listing with a price in the Drug Tariff. This information will be used to inform the reimbursement prices for special medicinal products. In addition, under the same Regulations, the Department can request ad-hoc information about sales and purchases as well as costs about any special medicinal products.</p><p> </p><p>The Health Service Medical Supplies (Costs) Act 2017 enables the Government to reimburse for specials dispensed in primary care in different ways such as considering quotes of suppliers and not reimbursing pharmacies at all if, for example, they have been provided the medicine by a central service. We are developing proposals, which will be subject to consultation with relevant stakeholders.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/07/2018 16:18:06 answering member 4067 label Biography information for Steve Brine
tabling member	4126 label Biography information for Mary Glindon

937735

registered interest
date	10/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he takes to ensure that drugs are sold to the NHS at a price which represents value for money to the public purse.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	162561
answer	answer is ministerial correction date of answer 17/07/2018 answer text <p>The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care competitive tenders ensure value-for-money to the National Health Service. Recent research published in the Milbank Quarterly demonstrated that the United Kingdom pays considerably less for unbranded generic medicines than other countries with a comparable income level.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/07/2018 13:53:50 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon